Fig. 4. Vepafestinib modulates expression of cell cycle and apoptosis markers.
a, LUAD-0002AS1 and TT cells were serum-staved for 24 h and then treated with 100 nM vepafestinib (TAS0953/HM06), selpercatinib, pralsetinib or vandetanib for 24 h. Following treatment, whole-cell extracts were prepared and subjected to western blotting analysis. Representative immunoblots from two independent experiments are shown. GAPDH was used as a sample-processing control. b, Cells were treated with the indicated RET inhibitors for 48 h before measuring caspase 3 and 7 enzymatic activity in cell homogenates. Results represent the mean ± s.d. of two independent experiments in which each condition was assayed in triplicate.